Differentiated Thyroid Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Differentiated thyroid cancer is a common cancer whose incidence is on the rise. It can have papillary or follicular histologies. In comparison to other malignancies, it has a better prognosis. The best outcomes, however, can only be achieved with a well-thought-out multimodal approach. The majority of thyroid cancers fall into one of the three categories of differentiated thyroid cancers (DTC): papillary, follicular, and Hurthle cell. DTC is a rare disease with mostly excellent prognosis. DTC occurs in 7-15% of patients with thyroid surgery. Surgery is the mainstay of early treatment for these therapies. The majority of patients should have a thyroidectomy along with a central neck (level VI) lymph node dissection. On the other hand, a thyroidectomy alone may be appropriate for people with smaller tumors (T1 or T2) and no symptoms of lymphadenopathy.

Description

Differentiated thyroid cancer is a common cancer whose incidence is on the rise. It can have papillary or follicular histologies. In comparison to other malignancies, it has a better prognosis. The best outcomes, however, can only be achieved with a well-thought-out multimodal approach. The majority of thyroid cancers fall into one of the three categories of differentiated thyroid cancers (DTC): papillary, follicular, and Hurthle cell. The follicular cells that make up the majority of the thyroid gland give rise to each and every one of them. Thyroid cancer with papillary growth is distinct. Papillary thyroid cancer accounts for about 80% of cases. The terms papillary carcinoma and papillary adenocarcinoma are also used to describe them. In most cases, they only occupy one thyroid lobe and grow slowly. Follicular thyroid cancer, also referred to as follicular carcinoma or follicular adenocarcinoma, is the second most prevalent type of thyroid cancer. It is responsible for just under 10% of thyroid cancer cases. It is more prevalent in regions where people do not consume enough of this crucial nutrient because a lack of iodine in the diet is the most common cause. Rare Hurthle cell cancers are also known as oxyphil cell carcinomas. They account for about 3% of thyroid cancer cases. The prognosis for this cancer is worse because it is more difficult to diagnose and treat.

Differentiated Thyroid Cancer (Epidemiology)

A rare condition with a largely positive prognosis is DTC. Age, sex, family history, exposure to radiation, and many other variables all affect how DTC manifests. DTC happens in 7-15% of thyroid surgery patients. In the US, women are more likely than men to develop DTC (22.3/100,000 vs. 7.7/100,000), about four times as likely. Global comparisons demonstrate an age-standardized incidence rate of 6/1,000,000 for women and 1/190/100,000 for men globally, reflecting this proportionality. Thyroid cancer is diagnosed at a younger average age than the majority of other serious cancers, currently 49 for females and 54 for males. Due to the increased use of diagnostic techniques, such as ultrasound of the neck, thyroid cancer incidence is on the rise, and the focus of tumor diagnosis has shifted from larger to smaller tumors. Papillary and follicular cancer, which originate from thyrocytes and express the sodium iodine symporter, are examples of differentiated thyroid cancer. Of all thyroid cancer types, DTC accounts for the vast majority (90%) of cases.

Differentiated Thyroid Cancer -Current Market Size & Forecast Trends

The market for differentiated thyroid cancer (DTC) treatment is projected to grow significantly, with estimates indicating a size of approximately USD 502.5 million in 2024, expected to reach around USD 2.09 billion by 2031, reflecting a compound annual growth rate (CAGR) of 22.60% during this period. The increasing prevalence of differentiated thyroid cancer, driven by lifestyle and environmental factors, alongside advancements in treatment options such as targeted therapies and improved diagnostic techniques, is fueling this market growth. North America is expected to dominate the market due to its advanced healthcare infrastructure and significant investments in cancer research, while the Asia Pacific region is anticipated to exhibit the highest growth rate. Overall, the differentiated thyroid cancer market is positioned for robust expansion through 2035 as new therapies continue to emerge and patient awareness increases.

Surgery is the mainstay of early treatment for these therapies. The majority of patients should have a thyroidectomy along with a central neck (level VI) lymph node dissection. On the other hand, a thyroidectomy alone may be appropriate for people with smaller tumors (T1 or T2) and no symptoms of lymphadenopathy. Surgery is also necessary in cases of cervical lymph node metastases and locoregional recurrence. Patients with metastatic disease or those who are at high risk for locoregional recurrence should take into account radioactive iodine, which is the primary adjuvant therapy. Similar to this, lowering endogenous thyroid-stimulating hormone is advised for people who have a high risk of recurrence. External-beam radiation should be administered to patients who have severe extrathyroidal expansion or persistent conditions that don't improve with surgery. Molecular therapies, in particular those that focus on significant tyrosine kinases and/or limit angiogenesis, have the potential to replace traditional chemotherapy due to its poor efficacy. A patient still develops drug resistance despite taking a variety of medications, which is just one of many unmet needs in the field of treating diseases. Furthermore, no distinct mechanism of VEGF inhibitor resistance has been discovered by researchers. As a result, second-line RET and NTRK inhibitor research is also advancing. It is still unknown, though, why patients who initially respond so well to medications like lenvatinib or cabozantinib later develop acquired resistance. Numerous clinical trials involving novel, developing drugs, including Apatinib (Advenchen Laboratories LLC), Dabrafenib (Novartis), Camrelizumab (Jiangsu Hengrui Medicine), Anlotinib (Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical), and others, are being conducted globally. These drugs may be able to fill some of the current gaps in care.

Report Highlights

Differentiated Thyroid Cancer - Current Market Trends

Differentiated Thyroid Cancer - Current & Forecasted Cases across the G8 Countries

Differentiated Thyroid Cancer - Market Opportunities and Sales Potential for Agents

Differentiated Thyroid Cancer - Patient-based Market Forecast to 2035

Differentiated Thyroid Cancer - Untapped Business Opportunities

Differentiated Thyroid Cancer - Product Positioning Vis-a-vis Competitors' Products

Differentiated Thyroid Cancer - KOLs Insight